New β2-Adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease

Drugs of Today

Volumn 46, Issue 12, 2010, Pages 911-918

  Schachter, E Neil ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIOXIDANT; ANTITUSSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; INDACATEROL; INFLUENZA VACCINE; LAS 100977; METHYLXANTHINE; MILVETEROL; MUCOLYTIC AGENT; NARCOTIC AGENT; OLODATEROL; ORCIPRENALINE; PF 00610355; PLACEBO; PNEUMOCOCCUS VACCINE; SALBUTAMOL; SALMETEROL; THERAVANCE; TIOTROPIUM BROMIDE; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILANTEROL;

ADD ON THERAPY; ANTIBIOTIC THERAPY; ASTHMA; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG BINDING SITE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INFECTION PREVENTION; LUNG INFECTION; MUCOCILIARY CLEARANCE; NONHUMAN; OXYGEN THERAPY; PROTEIN FUNCTION; PROTEIN STRUCTURE; PULMONARY REHABILITATION; REVIEW; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79955923007     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.12.1541552     Document Type: Review

References (60)

1. Ahlquist, R.P. Study of the adrenotropic receptors. Am J Physiol 1948, 53(3): 586-600.
2. Lands, A.M., Arnold, A., McAuliff, J.P. et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature (Lond) 1967, 214(5088): 597-8.
3. Kobilka, B.K., Dixon, R.A., Frielle, H.G. et al. cDNA for the human beta-2 adrenergic receptor. A protein with multiple spanning domains and encoded by a gene whose chromosome allocation is shared with that of a receptor for platelet growth factor. Proc Natl Acad Sci USA 1987, 84(1): 46-50.
4. Johnson, M. Molecular mechanisms of beta-2 adrenergic receptor function, response and regulation. J Allergy Clin Imunol 2006, 117(1): 18-24. (Pubitemid 43017132)
5. Mialet-Perez, J., Green, S.A., Miller, W.E. et al. A primate dominant third glycosilation site of the beta-2 adrenergic receptor routes receptor to degradation during agonist regulation. J Biol Chem 2004, 279(37): 38603-7. (Pubitemid 39296015)
6. Liggett, S. B. Update on current concepts of the molecular basis of beta-2 adrenergic receptor signaling. J Allerg Clin Immunol 2002, 110(Suppl.): S223-8.
7. Johnson, M., Coleman, R.A. Mechanism of action of beta-2 adrenoceptor agonists. In: Asthma & Rhinitis. Busse, W.W., Holgate, S.T. (Eds.). Blackwell: Cambridge, 1995, 1278-95.
8. Lehnert, B.E. Adrenergic receptors and amines. In: The Pharmacology of Respiratory Care. Lehnert, B.E., Schachter, E.N. (Eds.). CV Mosby: St. Louis, 1980, 172-90.
9. Johnson, M. Mechanism of action of beta 2 adrenoceptor agonists. In: Asthma and Rhinitis 2. Busse, W.W., Holgate, S.T. (Eds.). Blackwell: Cambridge, 2000, 1541-57.
10. Anderson, G.P., Linden, A., Rabe, K.F. Why are long-acting beta-adrenoceptor agonists long acting? Eur Resp J 1994, 7(3): 569-78.
11. Di Marco, F., Milic-Emili, J., Beroveri, B. et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnea at rest in COPD. Eur Respir J 2003, 21(1): 86-94.
12. O'Donnell, D.E., Voduc, N., Fitzpatrick, M. et al. Effect of salmeterol in the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004, 24(1): 86-94.
13. Broadley, K.J. Beta-adrenoreceptor responses of the airways: For better or worse? Eur J Pharm 2006, 533(1-3): 15-27.
14. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive pulmonary Disease. Executive Summary (Updated 2009). www.goldcopd.com.
15. Cazzola, M., Matera, M.G., Lotwall, J. Ultra-long acting beta-2 agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005, 14(7): 775-83. (Pubitemid 41030946)
16. Voss, H.P., Donnell, D., Bast, A. Atypical molecular pharmacology of a new long acting beta-2 adrenoceptor agonist, TA2005. Eur J Pharmacol 1992, 227(4): 403-9.
17. Voss, H.P., Shukrula, S., Wu. XS. et al. A functional adrenoreceptor-mediated, chronotropic response in isolated guinea pig heart tissue: Selectivity of the potent beta 2 adrenoceptor agonist TA2005. J Pharmacol Exp Ther 1994, 271(1): 386-89.
18. Naline, E., Trifilieff, A., Fairhurst, R.A. et al. Effect of indacaterol a novel long acting beta-2 agonist, on iosolated human bronchi. Eur Resp J 2007, 29(3): 575-81.
19. Sturton, R.C., Trifilieff, A., Nicholson, A.G. et al. Pharmacological characterization of indacaterol, a novel once daily inhaled beta-2 adrenoceptor agonist, on small airways in human and rat precision cut lung slices. J Pharmacol Exp Ther 2008, 324(1): 70-5.
20. Pearlman, D.S., Greos, L., LaForce, C. et al. Bronchodilator efficacy of single4 doses of indacaterol in patients with persistent asthma. Ann Allergy Asthma Immunol 2008, 101(1): 90-6.
21. Rennard, S., Bantje, T., Centanni, S. et al. A dose ranging study of indacaterol in obstructive airway disease, with ipatropium comparison. Respir Med 2008, 102(7): 1033-44.
22. Beier, J., Chanez, P., Martinot, J.B. et al. Safety and efficacy of indicaterol, a novel once daily beta-2 agonist, in patients with COPD: A 28 day randomized, placebo controlled, 28 day safety study. Ann Allergy Asthma Immunol 2007, 20(8): 740-9.
23. Bauwens, O., Ninane, V., Van de Maele, B. et al. 24-Hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: Comparison with placebo and formoterol. Curr Med Res Opin 2009, 25(2): 463-70.
24. Beeh, K.M., Beier, J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases. Adv Ther 2009, 26(7): 691-9.
25. Beier, J., Beeh, K.M., Pascoe, S. et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009, 22(6): 492-6.
26. th Int Conf Am Thorac Soc (May 15-20, San Diego) 2009] 2009, 179(Abstracts Issue): A4548.
27. Kornmann, O., Dahl, R., Centanni, S. et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: A placebo-controlled comparison. Eur Respir J 2010, Epub ahead of print.
28. Cazzola, M., Matera, M.G. Emerging inhaled bronchodilators:An update. Eur Respir J 2009, 34(3): 757-69.
29. Schnapp, A., Bouysou, T., Pestel, S. et al. Pharmacological profile of BI 1744 CL, a novel long acting adrenoceptor agonist. Proc Am Thorac Soc 2008, 5: A931.
30. Ward, J., Macintyre, F., Jones, I. et al. A randomized double blind study to determine the efficacy and safety of a once daily inhaled beta 2 adrenoceptor agonist, PF-00610355 in asthmatic patients. Eur Respir J 2009, 34: 778s.
31. Combivent Inhalation Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994, 105(5): 1411-9.
32. Van Noord, J.A., Aumann, J.L., Jansesens, E. et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Resp J 2005, 26(2): 214-22.
33. Van Noord, J.A., Aumann, J.L., Jansesens, E. et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 29(3): 509-17.
34. Tashkin, D.P., Littner, M., Andrews, C.P. et al. Concomittant treatment with nebulized formoterol and tiotropium in subjects with COPD, a placebo controlled trial. Respir Med 2008, 102(4): 479-87.
35. Vogelmeier, C., Kardos, P., Harari, S. et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD, a 6 month study. Respir Med 2008, 102(11): 1511-20.
36. Tashkin, D.P., Varghese, S.T. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm Pharmacol Ther 2010, Epub ahead of print.
37. van Noord, J.A., Aumann, J.L., Janssens, E. et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010, 104(7): 995-1004.
38. Aaron, S.D., Vandemheen, K.L., Fergusson, D. et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146(8): 545-55.
39. Cazzola, M., Andò, F., Santus, P., Ruggeri, P., Di Marco, F., Sanduzzi, A., D'Amato, M. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007, 20(5): 556-61. (Pubitemid 47077647)
40. Singh, D., Brooks, J., Hagan, G. et al. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008, 63(7): 592-8.
41. Celli, B.R., MacNee, W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6): 932-46.
42. Hanania, N.A., Donohue, J.F. Pharmacologic interventions in chronic obstructive pulmonary disease: Bronchodilators. Proc Am Thorac Soc 2007, 4(7): 526-34. (Pubitemid 47547847)
43. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004, 59(Suppl. 1): 1-232.
44. Rossi, A., Khirani, S., Cazzola, M. Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: Efficacy and safety. Int J Chron Obstruct Pulmon Dis 2008, 3(4): 521-9.
45. Calverley, P.M., Boonsawat, W., Cseke, Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22(6): 912-9. (Pubitemid 37540641)
46. Calverley, P., Pauwels, R., Vestbo, J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2003, 361(9356): 449-56. (Pubitemid 36173708)
47. Man, S.F., McAlister, F.A., Anthonisen, N. et al. Contemporary management of chronic obstructive pulmonary disease: Clinical applications. JAMA 2003, 290(17): 2313-6. (Pubitemid 37430564)
48. Calverley, P.M., Anderson, J.A., Celli, B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8): 775-89. (Pubitemid 46294610)
49. Calverley, P.M., Anderson, J.A., Celli, B. et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010, 65(8): 719-25.
50. Salpeter, S. Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: A systematic review. Drugs Aging 2004, 21(6): 405-14.
51. Donner, C.F. Inhaled beta2-adrenoceptar agonists: Cardiovascular safety in patients with obstructive lung disease. Drugs 2005, 65(12): 1595-610. (Pubitemid 41138983)
52. Cazzola, M., Segreti, A., Matera, M.G. Novel bronchodilators in asthma. Curr Opin Pulm Med 2010, 16(1): 6-12.
53. Ohar, J.A., Donohue, J.F. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med 2010, 31(3): 321-33.
54. Kottakis, I., Nandeuil, A., Raptis, H. et al. Efficacy of the novel very long acting beta-2 agonist carmoterol following 7 days once daily dosing, comparison with twice daily formoterol in patients with permanent asthma. Eur Resp J 2006, 28: 665s.
55. Nandeuil, A., Kottakis, I., Raptis, H. et al. Safety and tolerability of the novel very long acting beta-2 agonist carmoterol given as a 2 mcg QD dose, 8 days comparison with formoterol and placebo in patients with persistent asthma. Eur Resp J 2006, 28: 665s.
56. Brookman, L.J., Knowles, L.J., Barbier, M., Elharrar, B., Fuhr, R., Pascoe, S. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin 2007, 23(12): 3113-22.
57. Kanniess, F., Boulet, L.P., Pierzchala, W. et al. Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: A dose-ranging study. J Asthma 2008, 45(10): 887-92.
58. LaForce, C., Alexander, M., Deckelmann, R. et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: A 7-day dose-ranging study. Allergy 2008, 63(1): 103-11. (Pubitemid 350198242)
59. Glossop, P.A., Lane, C.A., Price, D.A. et al. Inhalation by design: Novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem 2010, 53(18): 6640-52.
60. Bouyssou, T., Casarosa, P., Naline, E. et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 2010, 334(1): 53-62.